Cannabis Use Among Individuals Treated with Medication for Opioid Use Disorder: Correlates, Patterns, and Motivations for Use
| Journal | Substance use & addiction journal |
| Study Type | Randomized Trial |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Cannabis use is prevalent among patients receiving medication for opioid use disorder (MOUD). However, little is known about factors associated with frequent cannabis use. To describe correlates, patterns, and motivations for cannabis use among individuals treated with MOUD. Participants from a randomized trial (n = 303) investigating a mind-body intervention adjunct to MOUD were compared based on frequent cannabis use (≥3 days/week) versus less frequent or no use, assessing demographic and clinical characteristics. Individuals with frequent cannabis use were invited to participate in a telephone survey exploring reasons for cannabis use, cannabis usage in treating symptoms/conditions, route, tetrahydrocannabinol/cannabidiol content, and cannabis use disorder screening. 47.5% of participants (n = 144) endorsed cannabis use, and 27% used cannabis frequently (≥3 days/week). Frequent cannabis use was associated with anxiety ( Frequent cannabis use among individuals on MOUD was associated
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
